Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.

about

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.

P2860

Q40102443-2D930DA9-9F3E-4D66-9101-9BCCD8B92477 Q48187737-D33D9988-0A82-4839-AD54-8FED2EA7C412

P2860

Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.

Item

http://www.wikidata.org/entity/Q40358008

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Brachytherapy improves outcome ...... state cancer: A SEER analysis.

@en

type

Item

label

Brachytherapy improves outcome ...... state cancer: A SEER analysis.

@en

prefLabel

Brachytherapy improves outcome ...... state cancer: A SEER analysis.

@en

P1476

Brachytherapy improves outcome ...... state cancer: A SEER analysis.

@en

P2093

Adel Guirguis

http://www.w3.org/2001/XMLSchema#string

Bahaa Mokhtar

http://www.w3.org/2001/XMLSchema#string

Clara Oromendia

http://www.w3.org/2001/XMLSchema#string

Daniel Metzger

http://www.w3.org/2001/XMLSchema#string

Evangelia Katsoulakis

http://www.w3.org/2001/XMLSchema#string

Hani Ashamalla

http://www.w3.org/2001/XMLSchema#string

Karla V Ballman

http://www.w3.org/2001/XMLSchema#string

Kyle McCool

http://www.w3.org/2001/XMLSchema#string

Mounzer Tchelebi

http://www.w3.org/2001/XMLSchema#string

Sameer Rafla

http://www.w3.org/2001/XMLSchema#string

P2860

Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries.

Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study

Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer.

Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.

Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis.

Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy

P304

323-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BRACHY.2016.12.010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Malcolm D. Mattes

P577

2017-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28139417

http://www.w3.org/2001/XMLSchema#string

P921

brachytherapy

P932

5568111

http://www.w3.org/2001/XMLSchema#string

Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.

about

P2860

P2860

Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932